Clinical trials: Recurrent Epithelial Ovarian Cancer
Ovarian Cancer
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
To evaluate the efficacy and safety of niraparib combined with oral etoposide in platinum resistant or platinum refractory recurrent ovarian cancer.
- Trial name
- NCT04217798
- Testing
- Niraparib
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Peking Union Medical College Hospital
Fallopian Tube Cancer, Ovarian Cancer
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of taurolidine in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00021034
- Testing
- chemotherapy, taurolidine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Solid Neoplasm, Estrogen Receptor Negative
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
This phase I trial studies the side effects and best dose of talazoparib and heat shock protein (HSP)90 inhibitor AT13387 when given together in treating patients with solid tumors that have spread to other places in the body…
- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, Fallopian Tube Serous Neoplasm, HER2/Neu Negative
- Trial name
- NCT02627430
- Testing
- Hsp90 Inhibitor AT13387, Laboratory Biomarker Analysis, Pharmacological Study
- Sponsor
- National Cancer Institute (NCI)
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
This phase II trial is studying how well vorinostat works in treating patients with recurrent or persistent ovarian epithelial or primary peritoneal cavity cancer.
- Trial name
- NCT00132067
- Testing
- vorinostat
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapy, Tumor
Autologous OC-DC Vaccine in Ovarian Cancer
This is a Five cohort sequential clinical trial for subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer to determine the feasibility and safety as well as immunogenicity of OC-DC, an autologous vaccine…
- Conditions
- Chemotherapy, Tumor, Ovarian Cancer
- Trial name
- NCT01132014
- Testing
- OCDC
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Ovarian Cancer
Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer
Multicenter, prospective, randomized studies.Evaluation of the sensitivity to different chemotherapy regimens in platinum-partial sensitive recurrent ovarian cancer based on 11 gene tests of homologous recombination pathway.
- Trial name
- NCT04337632
- Testing
- Doxorubicin Hydrochloride Liposome Injection+carboplatin, paclitaxel +carboplatin
- Where
- China
- Volunteers
- 338 people
- Sponsor
- Hunan Cancer Hospital
Recurrent Epithelial Cancer of Ovary, Primary Peritoneal Carcinoma
Anti-PD-L1 and SAbR for Ovarian Cancer
Programmed death-1 receptor ligand (PD-L1) the ligand for PD-1 is a key therapeutic target in the reactivation of the immune response against multiple cancers.
- Conditions
- Recurrent Epithelial Cancer of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03312114
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
Fallopian Tube Cancer, Ovarian Cancer
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to determine the effectiveness of imatinib mesylate in treating patients who have…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00039585
- Testing
- imatinib mesylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer
RATIONALE: Squalamine lactate may stop or slow the growth of ovarian cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00021385
- Testing
- carboplatin, squalamine lactate
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovarian Neoplasms, Ovarian Diseases
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
This is a single-arm, exploratory study. People with recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for ovarian cancer were selected to evaluate the efficacy and safety…
- Trial name
- NCT05753826
- Testing
- Adebrelimab, Fuzuloparib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
Ovarian Cancer
Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00002977
- Testing
- filgrastim, melphalan, thiotepa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fred Hutchinson Cancer Center
Estrogen Receptor Positive, Postmenopausal
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
This phase II trial studies how well ribociclib and letrozole work in treating patients with estrogen receptor (ER) positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer that has returned (come back) after a…
- Conditions
- Estrogen Receptor Positive, Postmenopausal, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02657928
- Testing
- Laboratory Biomarker Analysis, Letrozole, Ribociclib
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Ovarian Epithelial Cancer Recurrent, Fallopian Tube Cancer
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
Efficacy of PankoMab-GEX vs Placebo in maintaining a response to chemotherapy in advanced ovarian, fallopian tube or primary peritoneal cancer.
- Conditions
- Ovarian Epithelial Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01899599
- Testing
- PankoMab-GEX
- Where
- 50 sites in Germany, Hungary and 6 more
- Volunteers
- 216 people
- Sponsor
- Glycotope GmbH
Ovarian Cancer
Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence
Ovarian cancer is the third most common malignant tumor in China's female reproductive system in terms of incidence rate and the first in terms of mortality.
- Trial name
- NCT06558019
- Where
- China
- Volunteers
- 509 people
- Sponsor
- Lei Li
Cancer
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
The purpose of this study is to determine the recommended dose of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with cancer that does not respond to treatment or has returned.
- Trial name
- NCT01495663
- Testing
- I-131-CLR1404
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cellectar Biosciences, Inc.
Ovarian Cancer
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of OMP-54F28 when combined with paclitaxel and carboplatin. OMP-54F28 will be administered IV on Days 1 of each 21-day cycle.
- Trial name
- NCT02092363
- Testing
- OMP-54F28, Paclitaxel and Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Ovarian Cancer, Ovarian Cancer Recurrent
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer.
- Trial name
- MAIA-ovarian (NCT06888921)
- Testing
- COM701, Normal Saline
- Where
- 27 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- Compugen Ltd
Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
This randomized phase III trial studies paclitaxel and carboplatin see how well they work compared with paclitaxel and ifosfamide in treating patients with fallopian tube, or peritoneal cavity cancer that is newly diagnosed…
- Conditions
- Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT00954174
- Testing
- Carboplatin, Ifosfamide, Paclitaxel
- Where
- 538 sites in United States, South Korea
- Volunteers
- 637 people
- Sponsor
- GOG Foundation
Solid Tumor, Adult, Solid Tumor Cancer
Study of DF6215 in Patients With Advanced Solid Tumors
A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced…
- Trial name
- NCT06108479
- Testing
- DF6215, pembrolizumab, KEYTRUDA®
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- Dragonfly Therapeutics
Ovarian Neoplasms
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
This is a Phase II, randomized, multi-centre study aiming at comparing the efficacy of Olaparib and Cediranib vs. weekly Paclitaxel in terms of progression free survival (PFS) in platinum refractory or resistant recurrent ovarian…
- Trial name
- BAROCCO (NCT03314740)
- Testing
- Paclitaxel, Cediranib, Olaparib
- Where
- 6 sites in Italy
- Volunteers
- 123 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.